GlassScriptPhysician profile
Damothara Thiruppathi
NPI 1811002306
$5,611.78
in general payments reported to CMS, 2019-2025
23 companies · $590 in 2025
The $590 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $781 · 2021: $1,032 · 2022: $813 · 2023: $997 · 2024: $982 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,568.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $1,385.28 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $712.57 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $605.72 | 2019-2025 | Dyanavel Xr |
| Neos Therapeutics, LP | $558.18 | 2019-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $538.95 | 2019-2022 | |
| Pfizer INC. | $226.30 | 2019-2025 | |
| Glaxosmithkline, LLC. | $186.30 | 2019-2025 | Bexsero |
| Merck Sharp & Dohme LLC | $183.50 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Supernus Pharmaceuticals, INC. | $168.30 | 2021-2025 | Qelbree |
| Adlon Therapeutics L.P. | $156.96 | 2020-2021 | |
| Cranial Technologies, INC | $154.53 | 2019-2025 | Doc Band |
| Collegium Pharmaceutical, INC. | $153.46 | 2025 | Jornay Pm |
| Sobi, INC | $117.83 | 2019-2024 | |
| Genentech USA, INC. | $97.32 | 2019-2021 | |
| Sanofi Pasteur INC. | $67.11 | 2020-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $61.84 | 2019-2025 | Relexxii |
| Aytu Biopharma, INC. | $54.95 | 2024 | Karbinal |
| Cognoa, INC. | $51.45 | 2022 | |
| Dermira, INC. | $45.55 | 2020 | |
| Seqirus USA INC | $24.22 | 2021-2022 | |
| Biomarin Pharmaceutical INC. | $23.97 | 2025 | Voxzogo 1.2mg |
| Avion Pharmaceuticals | $20.58 | 2023 | Methylphenidate Hydrochloride |
| Novartis Pharmaceuticals Corporation | $16.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damothara Thiruppathi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.